#begin document (nw/wsj/14/wsj_1443); part 000
nw/wsj/14/wsj_1443   0    0        Immunex    NNP          (TOP(S(NP*           -    -   -   -   (ORG*   (ARG0*        *             *        *    (0
nw/wsj/14/wsj_1443   0    1          Corp.    NNP                   *)          -    -   -   -       *)       *)       *             *        *     0)
nw/wsj/14/wsj_1443   0    2           said    VBD                (VP*          say  01   1   -       *      (V*)       *             *        *     -
nw/wsj/14/wsj_1443   0    3            its   PRP$         (SBAR(S(NP*           -    -   -   -       *   (ARG1*   (ARG0*             *        *    (0)
nw/wsj/14/wsj_1443   0    4     scientists    NNS                   *)          -    -   -   -       *        *        *)            *        *     -
nw/wsj/14/wsj_1443   0    5       isolated    VBD                (VP*      isolate  01   2   -       *        *      (V*)            *        *     -
nw/wsj/14/wsj_1443   0    6              a     DT             (NP(NP*           -    -   -   -       *        *   (ARG1*        (ARG0*        *    (1
nw/wsj/14/wsj_1443   0    7       molecule     NN                   *)          -    -   -   -       *        *        *             *)       *     -
nw/wsj/14/wsj_1443   0    8          which    WDT         (SBAR(WHNP*)          -    -   -   -       *        *        *      (R-ARG0*)       *     -
nw/wsj/14/wsj_1443   0    9            may     MD              (S(VP*           -    -   -   -       *        *        *    (ARGM-MOD*)       *     -
nw/wsj/14/wsj_1443   0   10           hold     VB                (VP*         hold  01   5   -       *        *        *           (V*)       *     -
nw/wsj/14/wsj_1443   0   11      potential     JJ             (NP(NP*)          -    -   -   -       *        *        *        (ARG1*        *     -
nw/wsj/14/wsj_1443   0   12             as     IN                (PP*           -    -   -   -       *        *        *             *        *     -
nw/wsj/14/wsj_1443   0   13              a     DT             (NP(NP*           -    -   -   -       *        *        *             *        *     -
nw/wsj/14/wsj_1443   0   14      treatment     NN                   *)   treatment   -   1   -       *        *        *             *        *     -
nw/wsj/14/wsj_1443   0   15            for     IN                (PP*           -    -   -   -       *        *        *             *        *     -
nw/wsj/14/wsj_1443   0   16    disruptions    NNS          (NP(NP(NP*)          -    -   -   -       *        *        *             *   (ARG1*     -
nw/wsj/14/wsj_1443   0   17             of     IN                (PP*           -    -   -   -       *        *        *             *        *     -
nw/wsj/14/wsj_1443   0   18            the     DT                (NP*           -    -   -   -       *        *        *             *        *     -
nw/wsj/14/wsj_1443   0   19         immune     NN                   *           -    -   -   -       *        *        *             *        *     -
nw/wsj/14/wsj_1443   0   20             -    HYPH                   *           -    -   -   -       *        *        *             *        *     -
nw/wsj/14/wsj_1443   0   21         system     NN                 *)))          -    -   -   -       *        *        *             *        *)    -
nw/wsj/14/wsj_1443   0   22              ,      ,                   *           -    -   -   -       *        *        *             *        *     -
nw/wsj/14/wsj_1443   0   23        ranging    VBG                (VP*        range  01   1   -       *        *        *             *      (V*)    -
nw/wsj/14/wsj_1443   0   24           from     IN                (PP*           -    -   -   -       *        *        *             *   (ARG3*     -
nw/wsj/14/wsj_1443   0   25          organ     NN            (NP(NML*           -    -   -   -       *        *        *             *        *     -
nw/wsj/14/wsj_1443   0   26             -    HYPH                   *           -    -   -   -       *        *        *             *        *     -
nw/wsj/14/wsj_1443   0   27     transplant     NN                   *)          -    -   -   -       *        *        *             *        *     -
nw/wsj/14/wsj_1443   0   28      rejection     NN                   *)   rejection   -   2   -       *        *        *             *        *     -
nw/wsj/14/wsj_1443   0   29              ,      ,                   *)          -    -   -   -       *        *        *             *        *)    -
nw/wsj/14/wsj_1443   0   30             to     IN                (PP*           -    -   -   -       *        *        *             *   (ARG4*     -
nw/wsj/14/wsj_1443   0   31      allergies    NNS                (NP*           -    -   -   -       *        *        *             *        *     -
nw/wsj/14/wsj_1443   0   32            and     CC                   *           -    -   -   -       *        *        *             *        *     -
nw/wsj/14/wsj_1443   0   33         asthma     NN   *)))))))))))))))))          -    -   -   -       *        *)       *)            *)       *)    1)
nw/wsj/14/wsj_1443   0   34              .      .                  *))          -    -   -   -       *        *        *             *        *     -

nw/wsj/14/wsj_1443   0    0            The     DT  (TOP(S(NP*         -    -   -   -   *   (ARG1*        *   (1
nw/wsj/14/wsj_1443   0    1       molecule     NN           *)        -    -   -   -   *        *)       *    1)
nw/wsj/14/wsj_1443   0    2             is    VBZ        (VP*         be  01   1   -   *      (V*)       *    -
nw/wsj/14/wsj_1443   0    3            the     DT     (NP(NP*         -    -   -   -   *   (ARG2*        *    -
nw/wsj/14/wsj_1443   0    4          mouse     NN           *         -    -   -   -   *        *        *    -
nw/wsj/14/wsj_1443   0    5        version     NN           *)   version   -   2   -   *        *        *    -
nw/wsj/14/wsj_1443   0    6             of     IN        (PP*         -    -   -   -   *        *        *    -
nw/wsj/14/wsj_1443   0    7              a     DT     (NP(NP*         -    -   -   -   *        *   (ARG1*   (4
nw/wsj/14/wsj_1443   0    8        protein     NN           *)        -    -   -   -   *        *        *)   -
nw/wsj/14/wsj_1443   0    9         called    VBN        (VP*       call  01   5   -   *        *      (V*)   -
nw/wsj/14/wsj_1443   0   10            the     DT      (S(NP*         -    -   -   -   *        *   (ARG2*    -
nw/wsj/14/wsj_1443   0   11    interleukin     NN       (NML*         -    -   -   -   *        *        *    -
nw/wsj/14/wsj_1443   0   12             -    HYPH           *         -    -   -   -   *        *        *    -
nw/wsj/14/wsj_1443   0   13             4      CD           *)        -    -   -   -   *        *        *    -
nw/wsj/14/wsj_1443   0   14       receptor     NN     *)))))))        -    -   -   -   *        *)       *)   4)
nw/wsj/14/wsj_1443   0   15              .      .          *))        -    -   -   -   *        *        *    -

nw/wsj/14/wsj_1443   0    0          IL     NN    (TOP(S(NP*          -    -   -   -   *   (ARG1*           *        *        *         *   (5
nw/wsj/14/wsj_1443   0    1          -    HYPH             *          -    -   -   -   *        *           *        *        *         *    -
nw/wsj/14/wsj_1443   0    2          4      CD             *)         -    -   -   -   *        *)          *        *        *         *    5)
nw/wsj/14/wsj_1443   0    3          is    VBZ          (VP*          be  01   2   -   *      (V*)          *        *        *         *    -
nw/wsj/14/wsj_1443   0    4           a     DT       (NP(NP*          -    -   -   -   *   (ARG2*      (ARG0*        *        *         *    -
nw/wsj/14/wsj_1443   0    5     hormone     NN             *)         -    -   -   -   *        *           *)       *        *         *    -
nw/wsj/14/wsj_1443   0    6       which    WDT   (SBAR(WHNP*)         -    -   -   -   *        *    (R-ARG0*)       *        *         *    -
nw/wsj/14/wsj_1443   0    7     directs    VBZ        (S(VP*      direct  01   1   -   *        *         (V*)       *        *         *    -
nw/wsj/14/wsj_1443   0    8         the     DT       (NP(NP*          -    -   -   -   *        *      (ARG1*        *        *         *    -
nw/wsj/14/wsj_1443   0    9      growth     NN             *      growth   -   1   -   *        *           *        *        *         *    -
nw/wsj/14/wsj_1443   0   10         and     CC             *          -    -   -   -   *        *           *        *        *         *    -
nw/wsj/14/wsj_1443   0   11    function     NN             *)   function  01   6   -   *        *           *      (V*)       *         *    -
nw/wsj/14/wsj_1443   0   12          of     IN          (PP*          -    -   -   -   *        *           *   (ARG0*        *         *    -
nw/wsj/14/wsj_1443   0   13       white     JJ       (NP(NP*          -    -   -   -   *        *           *        *   (ARG1*         *    -
nw/wsj/14/wsj_1443   0   14       blood     NN             *          -    -   -   -   *        *           *        *        *         *    -
nw/wsj/14/wsj_1443   0   15       cells    NNS             *)       cell   -   1   -   *        *           *        *        *)        *    -
nw/wsj/14/wsj_1443   0   16    involved    VBN          (VP*     involve  01   1   -   *        *           *        *      (V*)        *    -
nw/wsj/14/wsj_1443   0   17          in     IN          (PP*          -    -   -   -   *        *           *        *   (ARG2*         *    -
nw/wsj/14/wsj_1443   0   18         the     DT       (NP(NP*          -    -   -   -   *        *           *        *        *    (ARG0*    -
nw/wsj/14/wsj_1443   0   19        body     NN             *        body   -   2   -   *        *           *        *        *         *    -
nw/wsj/14/wsj_1443   0   20          's    POS             *)         -    -   -   -   *        *           *        *        *         *)   -
nw/wsj/14/wsj_1443   0   21      immune     JJ             *          -    -   -   -   *        *           *        *        *    (ARG2*)   -
nw/wsj/14/wsj_1443   0   22    response     NN   *)))))))))))   response  01   2   -   *        *)          *)       *)       *)      (V*)   -
nw/wsj/14/wsj_1443   0   23           .      .            *))         -    -   -   -   *        *           *        *        *         *    -

nw/wsj/14/wsj_1443   0    0         The     DT  (TOP(S(NP(NP*         -    -   -   -   *   (ARG0*        *   (4
nw/wsj/14/wsj_1443   0    1          IL     NN          (NML*         -    -   -   -   *        *        *   (5
nw/wsj/14/wsj_1443   0    2          -    HYPH              *         -    -   -   -   *        *        *    -
nw/wsj/14/wsj_1443   0    3          4      CD              *)        -    -   -   -   *        *        *    5)
nw/wsj/14/wsj_1443   0    4    receptor     NN              *)        -    -   -   -   *        *        *    -
nw/wsj/14/wsj_1443   0    5          on     IN           (PP*         -    -   -   -   *        *        *    -
nw/wsj/14/wsj_1443   0    6         the     DT        (NP(NP*         -    -   -   -   *        *        *    -
nw/wsj/14/wsj_1443   0    7     surface     NN              *)        -    -   -   -   *        *        *    -
nw/wsj/14/wsj_1443   0    8          of     IN           (PP*         -    -   -   -   *        *        *    -
nw/wsj/14/wsj_1443   0    9        such     JJ           (NP*         -    -   -   -   *        *        *    -
nw/wsj/14/wsj_1443   0   10       cells    NNS          *)))))      cell   -   1   -   *        *)       *    4)
nw/wsj/14/wsj_1443   0   11    receives    VBZ           (VP*    receive  01   1   -   *      (V*)       *    -
nw/wsj/14/wsj_1443   0   12         the     DT        (NP(NP*         -    -   -   -   *   (ARG1*        *   (5
nw/wsj/14/wsj_1443   0   13     hormone     NN              *         -    -   -   -   *        *        *    -
nw/wsj/14/wsj_1443   0   14          's    POS              *)        -    -   -   -   *        *        *    5)
nw/wsj/14/wsj_1443   0   15     message     NN              *    message   -   1   -   *        *        *    -
nw/wsj/14/wsj_1443   0   16          to     TO         (S(VP*         -    -   -   -   *        *        *    -
nw/wsj/14/wsj_1443   0   17       rally     VB           (VP*      rally  01   1   -   *        *      (V*)   -
nw/wsj/14/wsj_1443   0   18         the     DT        (NP(NP*         -    -   -   -   *        *   (ARG1*    -
nw/wsj/14/wsj_1443   0   19        body     NN              *       body   -   2   -   *        *        *    -
nw/wsj/14/wsj_1443   0   20          's    POS              *)        -    -   -   -   *        *        *    -
nw/wsj/14/wsj_1443   0   21     defense     NN         *))))))   defense   -   5   -   *        *)       *)   -
nw/wsj/14/wsj_1443   0   22           .      .             *))        -    -   -   -   *        *        *    -

nw/wsj/14/wsj_1443   0    0             But    CC       (TOP(S*           -    -   -   -   *             *            *         *             *   -
nw/wsj/14/wsj_1443   0    1              in    IN          (PP*           -    -   -   -   *    (ARGM-ADV*            *         *             *   -
nw/wsj/14/wsj_1443   0    2         certain    JJ       (NP(NP*           -    -   -   -   *             *            *         *             *   -
nw/wsj/14/wsj_1443   0    3      conditions   NNS             *)   condition   -   1   -   *             *            *         *             *   -
nw/wsj/14/wsj_1443   0    4            such    JJ          (PP*           -    -   -   -   *             *            *         *             *   -
nw/wsj/14/wsj_1443   0    5              as    IN             *           -    -   -   -   *             *            *         *             *   -
nw/wsj/14/wsj_1443   0    6      autoimmune    JJ       (NP(NP*           -    -   -   -   *             *            *         *             *   -
nw/wsj/14/wsj_1443   0    7        diseases   NNS             *)          -    -   -   -   *             *            *         *             *   -
nw/wsj/14/wsj_1443   0    8             and    CC             *           -    -   -   -   *             *            *         *             *   -
nw/wsj/14/wsj_1443   0    9       allergies   NNS          (NP*)          -    -   -   -   *             *            *         *             *   -
nw/wsj/14/wsj_1443   0   10             and    CC             *           -    -   -   -   *             *            *         *             *   -
nw/wsj/14/wsj_1443   0   11      transplant    NN          (NP*           -    -   -   -   *             *            *         *             *   -
nw/wsj/14/wsj_1443   0   12       rejection    NN         *)))))   rejection   -   2   -   *             *)           *         *             *   -
nw/wsj/14/wsj_1443   0   13               ,     ,             *           -    -   -   -   *             *            *         *             *   -
nw/wsj/14/wsj_1443   0   14         doctors   NNS          (NP*)          -    -   -   -   *        (ARG0*)      (ARG0*)        *             *   -
nw/wsj/14/wsj_1443   0   15           would    MD          (VP*           -    -   -   -   *    (ARGM-MOD*)           *         *             *   -
nw/wsj/14/wsj_1443   0   16            like    VB          (VP*         like  02   1   -   *           (V*)           *         *             *   -
nw/wsj/14/wsj_1443   0   17              to    TO        (S(VP*           -    -   -   -   *        (ARG1*            *         *             *   -
nw/wsj/14/wsj_1443   0   18            damp    VB          (VP*         damp  01   1   -   *             *          (V*)        *             *   -
nw/wsj/14/wsj_1443   0   19             the    DT          (NP*           -    -   -   -   *             *       (ARG1*         *             *   -
nw/wsj/14/wsj_1443   0   20          immune    JJ             *           -    -   -   -   *             *            *    (ARG2*)            *   -
nw/wsj/14/wsj_1443   0   21        response    NN             *)    response  01   2   -   *             *            *)      (V*)            *   -
nw/wsj/14/wsj_1443   0   22              so    IN        (SBAR*           -    -   -   -   *             *   (ARGM-PNC*         *             *   -
nw/wsj/14/wsj_1443   0   23            such    JJ        (S(NP*           -    -   -   -   *             *            *         *        (ARG0*   -
nw/wsj/14/wsj_1443   0   24           cells   NNS             *)        cell   -   1   -   *             *            *         *             *)  -
nw/wsj/14/wsj_1443   0   25              do   VBP          (VP*           -    -   -   -   *             *            *         *             *   -
nw/wsj/14/wsj_1443   0   26             n't    RB             *           -    -   -   -   *             *            *         *    (ARGM-NEG*)  -
nw/wsj/14/wsj_1443   0   27           touch    VB          (VP*        touch  02   9   -   *             *            *         *           (V*)  -
nw/wsj/14/wsj_1443   0   28             off    RP         (PRT*)          -    -   -   -   *             *            *         *             *   -
nw/wsj/14/wsj_1443   0   29         harmful    JJ       (NP(NP*           -    -   -   -   *             *            *         *        (ARG1*   -
nw/wsj/14/wsj_1443   0   30    inflammatory    JJ             *           -    -   -   -   *             *            *         *             *   -
nw/wsj/14/wsj_1443   0   31       reactions   NNS             *)          -    -   -   -   *             *            *         *             *   -
nw/wsj/14/wsj_1443   0   32              or    CC             *           -    -   -   -   *             *            *         *             *   -
nw/wsj/14/wsj_1443   0   33            cell    NN          (NP*         cell   -   1   -   *             *            *         *             *   -
nw/wsj/14/wsj_1443   0   34     destruction    NN   *)))))))))))          -    -   -   -   *             *)           *)        *             *)  -
nw/wsj/14/wsj_1443   0   35               .     .            *))          -    -   -   -   *             *            *         *             *   -

nw/wsj/14/wsj_1443   0    0              A    DT  (TOP(S(S(NP(NP*          -    -   -   -   *        (ARG0*         *   (ARG1*    -
nw/wsj/14/wsj_1443   0    1        soluble    JJ                *          -    -   -   -   *             *         *        *    -
nw/wsj/14/wsj_1443   0    2           form    NN                *)       form   -   4   -   *             *         *        *    -
nw/wsj/14/wsj_1443   0    3             of    IN             (PP*          -    -   -   -   *             *         *        *    -
nw/wsj/14/wsj_1443   0    4            the    DT             (NP*          -    -   -   -   *             *         *        *   (4
nw/wsj/14/wsj_1443   0    5       receptor    NN              *)))         -    -   -   -   *             *)        *        *    4)
nw/wsj/14/wsj_1443   0    6          might    MD             (VP*          -    -   -   -   *    (ARGM-MOD*)        *        *    -
nw/wsj/14/wsj_1443   0    7           turn    VB             (VP*        turn  07   5   -   *           (V*)        *        *    -
nw/wsj/14/wsj_1443   0    8            off    RP            (PRT*)         -    -   -   -   *             *         *        *    -
nw/wsj/14/wsj_1443   0    9              a    DT          (NP(NP*          -    -   -   -   *        (ARG1*         *        *    -
nw/wsj/14/wsj_1443   0   10       specific    JJ                *          -    -   -   -   *             *         *        *    -
nw/wsj/14/wsj_1443   0   11           part    NN                *)       part   -   1   -   *             *         *        *    -
nw/wsj/14/wsj_1443   0   12             of    IN             (PP*          -    -   -   -   *             *         *        *    -
nw/wsj/14/wsj_1443   0   13            the    DT             (NP*          -    -   -   -   *             *         *        *    -
nw/wsj/14/wsj_1443   0   14         immune    JJ                *          -    -   -   -   *             *    (ARG2*)       *    -
nw/wsj/14/wsj_1443   0   15       response    NN              *)))   response  01   2   -   *             *)      (V*)       *    -
nw/wsj/14/wsj_1443   0   16        without    IN             (PP*          -    -   -   -   *    (ARGM-MNR*         *        *    -
nw/wsj/14/wsj_1443   0   17        general    JJ             (NP*          -    -   -   -   *             *         *        *    -
nw/wsj/14/wsj_1443   0   18         immune    JJ                *          -    -   -   -   *             *         *        *    -
nw/wsj/14/wsj_1443   0   19    suppression    NN            *)))))         -    -   -   -   *             *)        *        *)   -
nw/wsj/14/wsj_1443   0   20              ,     ,                *          -    -   -   -   *             *         *        *    -
nw/wsj/14/wsj_1443   0   21            the    DT             (NP*          -    -   -   -   *             *         *   (ARG0*   (0
nw/wsj/14/wsj_1443   0   22        company    NN                *)    company   -   1   -   *             *         *        *)   0)
nw/wsj/14/wsj_1443   0   23           said   VBD             (VP*)        say  01   1   -   *             *         *      (V*)   -
nw/wsj/14/wsj_1443   0   24              .     .               *))         -    -   -   -   *             *         *        *    -

nw/wsj/14/wsj_1443   0    0          The     DT    (TOP(S(NP*          -    -   -   -            *   (ARG1*      *        *            *         *             *       (4
nw/wsj/14/wsj_1443   0    1           IL     NN         (NML*          -    -   -   -            *        *      *        *            *         *             *       (5
nw/wsj/14/wsj_1443   0    2           -    HYPH             *          -    -   -   -            *        *      *        *            *         *             *        -
nw/wsj/14/wsj_1443   0    3           4      CD             *)         -    -   -   -            *        *      *        *            *         *             *        5)
nw/wsj/14/wsj_1443   0    4     receptor     NN             *)         -    -   -   -            *        *)     *        *            *         *             *        4)
nw/wsj/14/wsj_1443   0    5           is    VBZ          (VP*          be  01   2   -            *      (V*)     *        *            *         *             *        -
nw/wsj/14/wsj_1443   0    6          one     CD       (NP(NP*)         -    -   -   -    (CARDINAL)  (ARG2*      *        *            *         *             *        -
nw/wsj/14/wsj_1443   0    7           of     IN          (PP*          -    -   -   -            *        *      *        *            *         *             *        -
nw/wsj/14/wsj_1443   0    8         five     CD       (NP(NP*          -    -   -   -    (CARDINAL)       *      *   (ARG1*       (ARG1*         *             *       (3
nw/wsj/14/wsj_1443   0    9         such     JJ             *          -    -   -   -            *        *      *        *            *         *             *        -
nw/wsj/14/wsj_1443   0   10    receptors    NNS             *)         -    -   -   -            *        *      *        *)           *)        *             *        -
nw/wsj/14/wsj_1443   0   11           to     TO   (SBAR(S(VP*          -    -   -   -            *        *      *        *            *         *             *        -
nw/wsj/14/wsj_1443   0   12           be     VB          (VP*          be  03   -   -            *        *    (V*)       *            *         *             *        -
nw/wsj/14/wsj_1443   0   13    developed    VBN          (VP*     develop  02   1   -            *        *      *      (V*)           *         *             *        -
nw/wsj/14/wsj_1443   0   14          and     CC             *          -    -   -   -            *        *      *        *            *         *             *        -
nw/wsj/14/wsj_1443   0   15       tested    VBN             *        test  01   1   -            *        *      *        *          (V*)        *             *        -
nw/wsj/14/wsj_1443   0   16           by     IN          (PP*          -    -   -   -            *        *      *   (ARG0*       (ARG0*         *             *        -
nw/wsj/14/wsj_1443   0   17    Receptech    NNP       (NP(NP*          -    -   -   -        (ORG*        *      *        *            *         *             *       (2
nw/wsj/14/wsj_1443   0   18        Corp.    NNP             *)         -    -   -   -            *)       *      *        *            *         *             *        -
nw/wsj/14/wsj_1443   0   19            ,      ,             *          -    -   -   -            *        *      *        *            *         *             *        -
nw/wsj/14/wsj_1443   0   20            a     DT       (NP(NP*          -    -   -   -            *        *      *        *            *         *             *        -
nw/wsj/14/wsj_1443   0   21      spinoff     NN             *)         -    -   -   -            *        *      *        *            *         *             *        -
nw/wsj/14/wsj_1443   0   22           of     IN          (PP*          -    -   -   -            *        *      *        *            *         *             *        -
nw/wsj/14/wsj_1443   0   23      Immunex    NNP      (NP*)))))         -    -   -   -         (ORG)       *      *        *)           *)        *             *    (0)|2)
nw/wsj/14/wsj_1443   0   24            ,      ,             *          -    -   -   -            *        *      *        *            *         *             *        -
nw/wsj/14/wsj_1443   0   25      through     IN          (PP*          -    -   -   -            *        *      *        *   (ARGM-MNR*         *             *        -
nw/wsj/14/wsj_1443   0   26            a     DT          (NP*          -    -   -   -            *        *      *        *            *         *             *        -
nw/wsj/14/wsj_1443   0   27     proposed    VBN             *     propose  01   1   -            *        *      *        *            *       (V*)            *        -
nw/wsj/14/wsj_1443   0   28            $      $      (NML(QP*          -    -   -   -      (MONEY*        *      *        *            *         *        (ARG2*        -
nw/wsj/14/wsj_1443   0   29          30      CD             *          -    -   -   -            *        *      *        *            *         *             *        -
nw/wsj/14/wsj_1443   0   30      million     CD            *))         -    -   -   -            *)       *      *        *            *         *             *)       -
nw/wsj/14/wsj_1443   0   31      initial     JJ             *          -    -   -   -            *        *      *        *            *         *    (ARGM-TMP*)       -
nw/wsj/14/wsj_1443   0   32       public     JJ             *          -    -   -   -            *        *      *        *            *         *        (ARG3*)       -
nw/wsj/14/wsj_1443   0   33     offering     NN   *)))))))))))   offering  01   1   -            *        *)     *        *            *)   (ARG1*)          (V*)       3)
nw/wsj/14/wsj_1443   0   34            .      .            *))         -    -   -   -            *        *      *        *            *         *             *        -

nw/wsj/14/wsj_1443   0    0        Immunex   NNP   (TOP(S(NP*)            -    -   -   -    (ORG)       (ARG0*)   (ARG0*)     *    (0)
nw/wsj/14/wsj_1443   0    1           will    MD         (VP*             -    -   -   -       *    (ARGM-MOD*)        *      *     -
nw/wsj/14/wsj_1443   0    2       contract    VB         (VP*       contract  02   1   -       *           (V*)        *      *     -
nw/wsj/14/wsj_1443   0    3           with    IN         (PP*             -    -   -   -       *        (ARG2*         *      *     -
nw/wsj/14/wsj_1443   0    4            the    DT         (NP*             -    -   -   -       *             *         *      *    (2
nw/wsj/14/wsj_1443   0    5        spinoff    NN           *))            -    -   -   -       *             *)        *      *     2)
nw/wsj/14/wsj_1443   0    6             to    TO       (S(VP*             -    -   -   -       *        (ARG1*         *      *     -
nw/wsj/14/wsj_1443   0    7        provide    VB         (VP*        provide  01   1   -       *             *       (V*)     *     -
nw/wsj/14/wsj_1443   0    8            the    DT      (NP(NP*             -    -   -   -       *             *    (ARG1*      *     -
nw/wsj/14/wsj_1443   0    9       research    NN            *)      research   -   1   -       *             *         *      *     -
nw/wsj/14/wsj_1443   0   10              ,     ,            *             -    -   -   -       *             *         *      *     -
nw/wsj/14/wsj_1443   0   11    development    NN         (NP*)   development  02   1   -       *             *         *    (V*)    -
nw/wsj/14/wsj_1443   0   12            and    CC            *             -    -   -   -       *             *         *      *     -
nw/wsj/14/wsj_1443   0   13        initial    JJ      (NP(NP*             -    -   -   -       *             *         *      *     -
nw/wsj/14/wsj_1443   0   14        testing    NN            *)          test   -   1   -       *             *         *      *     -
nw/wsj/14/wsj_1443   0   15             of    IN         (PP*             -    -   -   -       *             *         *      *     -
nw/wsj/14/wsj_1443   0   16            the    DT         (NP*             -    -   -   -       *             *         *      *    (3
nw/wsj/14/wsj_1443   0   17            new    JJ            *             -    -   -   -       *             *         *      *     -
nw/wsj/14/wsj_1443   0   18         agents   NNS    *)))))))))         agent   -   1   -       *             *)        *)     *     3)
nw/wsj/14/wsj_1443   0   19              .     .           *))            -    -   -   -       *             *         *      *     -

nw/wsj/14/wsj_1443   0    0      Immunex   NNP   (TOP(S(NP*)       -    -   -   -     (ORG)       (ARG0*)       (ARG0*)   (0)
nw/wsj/14/wsj_1443   0    1         will    MD         (VP*        -    -   -   -        *    (ARGM-MOD*)            *     -
nw/wsj/14/wsj_1443   0    2         have    VB         (VP*      have  03   2   -        *           (V*)            *     -
nw/wsj/14/wsj_1443   0    3          the    DT         (NP*        -    -   -   -        *        (ARG1*             *     -
nw/wsj/14/wsj_1443   0    4       option    NN            *    option   -   2   -        *             *             *     -
nw/wsj/14/wsj_1443   0    5           to    TO       (S(VP*        -    -   -   -        *             *             *     -
nw/wsj/14/wsj_1443   0    6          buy    VB         (VP*       buy  01   1   -        *             *           (V*)    -
nw/wsj/14/wsj_1443   0    7         back    RP        (PRT*)       -    -   -   -        *             *    (ARGM-DIR*)    -
nw/wsj/14/wsj_1443   0    8    Receptech   NNP         (NP*        -    -   -   -     (ORG)            *        (ARG1*    (2)
nw/wsj/14/wsj_1443   0    9       shares   NNS            *)    share   -   2   -        *             *             *)    -
nw/wsj/14/wsj_1443   0   10        after    IN         (PP*        -    -   -   -        *             *    (ARGM-TMP*     -
nw/wsj/14/wsj_1443   0   11         five    CD         (NP*        -    -   -   -   (DATE*             *             *     -
nw/wsj/14/wsj_1443   0   12        years   NNS     *))))))))       -    -   -   -        *)            *)            *)    -
nw/wsj/14/wsj_1443   0   13            .     .           *))       -    -   -   -        *             *             *     -

#end document
